SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GMED - GenoMed Inc.
GMED 55.90-0.4%12:04 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jmhollen who wrote (318)11/5/2006 1:36:11 PM
From: Tadsamillionaire   of 347
 
Annals Publishes GenoMed's Approach to Avian Influenza
GenoMed(TM) (OTC Pink Sheets:GMED), the Next Generation Disease Management company whose business is public health(TM), announced today that its approach to avian influenza ("bird flu") has been published by the prestigious journal Annals of Internal Medicine.
October 24, 2006 - 10:12 AM EST
(http://www.annals.org/cgi/eletters/145/8/631#3964).

Said Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, "GenoMed is honored to have created a debate within the virology community about whether it's the viral load or the 'cytokine storm' which kills a patient with a lethal viral disease like avian influenza. Three years ago we applied for a patent saying that the 'cytokine storm' alone was lethal, and that the viral load could essentially be ignored. Two years ago, we published that our purely anti-inflammatory approach appears to work for another lethal viral disease, West Nile virus encephalitis."

Dr. Moskowitz continued, "We're eager to keep testing this hypothesis. If we're right, it will transform the way viral diseases are treated in the general population."

Added Dr. Moskowitz, "At this point, as with the rest of our treatments, the only element missing is public awareness. We're reminded every day that if people with viral disease, high blood pressure, diabetes, or emphysema only knew about us, we might be able to help save their lives."

About GenoMed

GenoMed owns "use" patents (which are pending) for the use of already existing, safe blood pressure pills to treat many diseases besides high blood pressure, including avian influenza. GenoMed estimates that it can already save 10% of healthcare costs and extend life by several years. The company is currently trying to publicize its intellectual property, since having cures is useless if nobody knows about them.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext